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Abstract
Background: This study aimed to investigate the long-term mortality and recurrence rate of stroke in first-time
stroke patients with symptomatic isolated middle cerebral artery disease (MCAD) under medical management.
Methods: We identified 141 first ever stroke patients (mean age, 64.4 ± 12.5 years; 53% male) with symptomatic
isolated MCAD. MCAD was defined as significant stenosis of more than 50% or occlusion of the MCA as revealed
by MR angiography. The median follow-up was 27.7 months. We determined a cumulative rate of stroke
recurrence and mortality by Kaplan-Meier survival analyses and sought predictors using the Cox proportional
hazard model.
Results: The cumulative composite outcome rate (stroke recurrence or any-cause death) was 14%, 19%, 22%, and
28% at years 1, 2, 3, and 5, respectively. The annual recurrence rate of stroke was 4.1%. The presence of diabetes
mellitus was the only significant independent predictor of stroke recurrence or any cause of death in multivariate
analyses of Cox proportional hazard model adjusted for any plausible potential confounding factors.
Conclusions: We estimated the long-term prognosis of stroke patients with isolated symptomatic MCAD under
current medical management in Korea. Diabetes mellitus was found to be a significant predictor for stroke
recurrence and mortality.
Background
Intracranial arterial disease is an important cause of
ischemic stroke, especially in Asian populations. Accord-
ing to previous studies, the prevalence of intracranial
arterial disease is approximately 8-10% in Caucasian
stroke patients [1-3]. In Asian stroke patients, the preva-
lence ranges from 31% up to as high as 50% [4-7], and
middle cerebral artery stenosis is the most common vas-
cular lesion [8]. In the Korean stroke registry, which is a
prospective multicenter hospital-based stroke databank
compiled by 26 university hospitals in Korea, large
artery atherosclerosis accounted for 36% of all ischemic
stroke subtypes [9]. Vascular lesions, based on magnetic
resonance angiography (MRA), were most commonly
found in the middle cerebral artery in 34.8% of patients
[10].
Despite the high prevalence of middle cerebral artery
disease (MCAD), the natural history and prognosis of
stroke patients with MCAD remain unknown. Previous
studies showed that patients with MCAD were at a high
risk of stroke recurrence [11-13], and the annual stroke
risk was between 4% and 15%, even though the patients
received medical management [14]. These reports, how-
ever, had some limitations because they did not exclude
stroke patients with either ipsilateral carotid artery ste-
nosis or a cardioembolic source. Very few reports have
focused on the natural history and prognosis of stroke
patients with isolated MCAD. Recently, intracranial
angioplasty/stenting has been proposed as a promising
treatment for patients with cerebral ischemic events
[15,16]. However, this procedure has been associated
with a short-term morbidity rate of 10-33.3%, a mortal-
ity rate of 2.5-8.3%, and a re-stenosis rate of 0-50% after
a few months of follow-up [17-19]. Therefore, knowl-
edge of the natural course of MCAD and the effect of
current optimal medical therapy is necessary.
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any medium, provided the original work is properly cited.The objective of this study was to investigate the long-
term stroke recurrence rate and mortality of sympto-
matic isolated MCAD managed by current medical ther-
apy. We also attempted to identify potential predictors
for stroke recurrence and mortality in these patients.
Methods
Between March 2002 and December 2007, 2,254
patients were admitted to Hallym University Sacred
Heart Hospital within seven days of the onset of symp-
toms of an acute ischemic stroke or transient ischemic
attack (TIA). We selected patients with neurological def-
icits correlated with ischemic events in the MCA terri-
tory and in whom MRA showed definitive evidence of
MCAD. Patients with a cardiogenic embolic source or
non-atherosclerotic causes of ischemic stroke, such as
vasculitis, vasospasm, dissection, aneurysm, or Moya-
moya disease, or with evidence of recurrent stroke were
excluded. We also excluded patients with significant ste-
nosis of extracranial or other major intracranial arteries.
We defined MCAD as the presence of a significant
stenosis of more than 50% or occlusion as revealed by
MRA (Philips Gyroscan Intera, 1.5 T, 3D TOF MR: 35/
9.6 TR/TE, flip angle 25°, 256 × 512 matrix size, 200-
mm field of view, 32-mm slab thickness). When MRA
reports did not specify the percentage of stenosis,
descriptive terms, such as “severe stenosis”, “high- or
moderate-grade stenosis”,o r“flow gap” (discontinuity of
the blood flow column signal with distal reconstitution),
were accepted as evidence of more than 50% stenosis.
For all cases with complete MCA occlusion, we per-
formed extensive etiological work-ups, including transe-
sophageal echocardiography and 24-hour holter
monitoring, to rule out the possibility of an embolic ori-
gin. We additionally repeated transcrainal doppler to
identify the recanalization or persistence of MCA occlu-
sion before discharge.
We reviewed the medical records of patients and
determined the demographic characteristics, risk factors,
and medical management during the follow-up period,
and timing of new stroke events or death. However, for
patients who had been referred to primary care physi-
cians at the time of discharge, we conducted a telephone
interview to assess their compliance with the manage-
ment for the prevention of secondary stroke and the
occurrence of any new stroke events or mortality.
Stroke recurrence was defined as clinical manifesta-
tions of neurological deficits correlated with a new
lesion in CT or MRI brain imaging. The composite out-
come of stroke recurrence or any-cause death was eval-
uated during the follow-up period to elucidate the long-
term prognosis of symptomatic isolated MCAD.
The study protocol was approved by local ethics com-
mittee of Hallym University Sacred Heat Hospital.
Statistical Analyses
In the statistical analysis, a Kaplan-Meier curve was gen-
erated for the cumulative probabilities of stroke recur-
r e n c ea n dc o m p o s i t eo u t c o m e( s t r o k er e c u r r e n c eo r
any-cause death). We used the Cox proportional hazard
regression for univariate and multivariate analyses to
identify potential predictors of stroke recurrence or any-
cause death. Patients lost for follow-up were censored at
the last contact date in the analyses. All data were ana-
lyzed using SPSS (version 10.0) software.
Results
During the study period, 520 (23.0% of the total) acute
stroke patients with MCAD were admitted to our hospi-
tal. Among them, 180 patients were diagnosed to have
significant MCAD as a unique cause of TIA or stroke,
and 141 with first-time stroke with symptomatic isolated
MCAD were chosen as the final study subjects.
The mean age was 64.4 ± 12.5 years, and 53% of the
patients were male. The distribution of the baseline
characteristics is listed in Table 1. As a qualifying event,
130 (92.2%) patients had ischemic stroke and 11 (7.8%)
had TIA. The mean NIHSS score at the time of admis-
sion was 6.1 (range 0 to 25; median 4.0), and the mean
modified Rankin scale at discharge was 2.1 (range 0 to
5; median 2.0). Ninety-eight patients had symptomatic
isolated MCA stenosis, and 43 patients had complete
occlusion of the MCA.
The median follow-up was 27.7 months. Sixty-six
(47%) patients were treated at our hospital for secondary
prevention, and 31 (22%) patients were referred to pri-
mary care physicians after discharge. We were unable to
follow-up with 28 (19%) patients. Sixteen (11.3%)
patients died during the follow-up periods. The cause of
death was classified as ischemic (n = 2) or hemorrhagic
(n = 1) stroke in three patients, 1 died from ischemic
heart disease, 2 from sudden death, 3 from cancer, 4
from pulmonary causes (pneumonia or pulmonary
embolism), and 3 from miscellaneous causes. At the last
follow-up, all patients were put on antithrombotics,
such as aspirin, clopidogrel, or cilostazol, and had
appropriate management for risk factors: of 141 patients
with symptomatic isolated MCAD, 67% were on anti-
hypertensive medication, 31.2% were on anti-diabetic
medication, and 47.2% were on lipid-lowering agent.
During the follow-up period, 29 composite outcomes
were documented. The cumulative stroke recurrence or
any-cause death rate was 14% at one year, 19% at two
years, 22% at three years, and 26% at four years, and the
five-year cumulative recurrence of stroke or death rate
was 28% in the Kaplan-Meier plots (Figure 1(a)).
Stroke recurrence was noted in 16 patients, resulting in
an overall annual rate of 4.1%. Eleven events (68.7%)
occurred in the vascular territory of symptomatic
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Page 2 of 8ipsilateral MCAD. Stroke out of the territory of the symp-
tomatic MCAD occurred in 5 (31.3%) of the 16 patients.
All events were ischemic stroke. Stroke events ipsilateral
to the MCAD occurred at a mean of 10.4 months after the
qualifying event, and recurrent stroke in remote or other
territories occurred after 14.5 months.
Using the Kaplan-Meier method (Figure 1(b)), the
cumulative stroke recurrence rate was estimated to be
9.7% at year one, 10.8% at year two, 12.4% at year three,
and 16.8% at year five.
No significant difference between MCA stenosis and
MCA occlusion was noted for the cumulative probabil-
ities of stroke recurrence or any cause of death (Figure 2).
In the univariate analyses conducted to identify the
potential predictors for the composite outcome, the pre-
sence of diabetes mellitus was the only significant factor
(HR = 2.16, 95% CI = 1.04-4.49) (Table 2). In the multivari-
ate analyses of the Cox proportional hazard model adjusted
for any plausible potential confounding factors such as age,
sex, MCA occlusion vs. stenosis, and the time from stroke
onset to admission, which were associated with the prog-
nosis of MCAD in a previous study[7,20], the presence of
diabetes mellitus was significant as an independent predic-
tor of the composite outcome (Table 3).
Discussion
We used MRA to verify 141 first-time ischemic stroke
patients with symptomatic isolated MCAD and analyzed
the long-term prognosis of stroke recurrence rate and
mortality for isolated MCAD. The one-year cumulative
stroke recurrence or any-cause death rate was 14%, and
the five-year cumulative stroke recurrence or death rate
was 28%. The annual recurrence rate was 4.1%, and the
cumulative rate was 9.7% at year one and 16.8% at year
five in patients with isolated MCAD under the current
standard medical treatment, including antithrombotics
and strict control of risk factors such as hypertension and
diabetes mellitus, statins for hyperlipidemia, and smoking
cessation. As an independent predictor of stroke recur-
rence or any-cause death, diabetes mellitus was significant.
The prognosis of patients with MCAD under conser-
vative medical therapy has varied among different stu-
dies because they used different diagnostic tools, and
MCAD may occur separately or in conjunction with car-
otid artery diseases [21,22]. Previous studies have
reported that the recurrence rate of stroke is 2-24%, and
the mortality rate is 0-29% in patients with MCAD
[21,23-25]. In our study, the overall annual rate of
stroke recurrence was 4.1%, which appeared to be more
favorable than the results of a previous study, in which
cerebrovascular events (TIA and stroke) occurred in
11.7% of the patients per year during follow-up (42
months) of 164 medically treated patients enrolled in
the Extracranial/Intracranial Bypass Study [26].
The previous studies reported that the rate of stroke
recurrence was similar in patients with severe MCA
Table 1 The comparison of baseline characteristics between the patients with symptomatic isolated MCA disease
(IMCAD) and those without.
With symptomatic IMCAD (N = 141) Without symptomatic IMCAD (N = 2,113)
Age - mean (SD), years 64.4 (12.5) 66.1 (12.3)
Male sex (%) 74 (52.5) 1,145 (54.2)
Hypertension - no. (%) 87 (61.7) 1,417 (67.1)
Diabetes mellitus - no. (%) 40 (28.4) 664 (31.4)
Smoking (ever) - no. (%) 46 (32.6) 648 (30.7)
Dyslipidemia - no. (%) 53 (37.6) * 419 (19.8)
Time from stroke onset to admission
≤ 24 hours - no. (%) 78 (55.3) 1,230 (58.2)
> 24 hours - no (%) 63 (44.7) 883 (41.8)
Qualifying event
Stroke - no. (%) 130 (92.2)* 2,208 (96.0)
TIA - no. (%) 11 (7.8) 85 (4.0)
NIHSS on admission - mean (SD) 6.1 (6.0) 5.8 (6.1)
Median 4.0 3.0
mRS on discharge - mean (SD) 2.1 (1.5) 2.0 (1.6)
median 2.0 2.0
IMCAD
≥ 50% MCA stenosis 98 (69.5)
MCA occlusion 43 (30.5)
IMCAD = Isolated Middle Cerebral Artery Disease; SD = Standard Deviation; TIA = Transient Ischemic Attack
* P < 0.05
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found that the long-term prognosis, stroke recurrence
and any-cause death in patients with MCA occlusion
did not differ from patients with MCA stenosis.
Patients with symptomatic MCAD are regarded as
being at high risk for recurrent cerebrovascular events
[11,14,27,31,32]. The cumulative recurrence rate of
symptomatic MCAD seems to be even higher than that
Figure 1 The Kaplan-Meier curves show (a) the cumulative probabilities of stroke recurrence or any-cause death and (b) stroke
recurrence during the observation period.
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Therefore, alternative therapies, such as aggressive man-
agement of risk factors, other antiplatelet regimens, and
intracranial angioplasty/stenting, are needed. Intracranial
angioplasty and stenting has been explored as a promis-
ing treatment for patients with symptomatic intracranial
stenosis [15,16]. However, the first prospective rando-
mized study, stenting versus aggressive medical manage-
ment for preventing recurrent stroke in intracranial
stensosis (SAMMPRIS), has very recently been halted
because high complication rate in the stenting arm (14%
patients had a stroke or died in the 30-day period after
stenting compared to only 5.8% in the medical arm)
[34]. Although the medical management in order to
achieve target levels based on national guidelines during
the follow-up was identical in the two groups, there
were significantly differences between two groups with
Figure 2 The Kaplan-Meier curves show the cumulative rate of recurrent stroke or any cause of death during the observation period.
Comparison of the patients with occlusion (upper curve) and with ≥ 50% stenosis (lower curve).
Table 2 Potential predictors of stroke recurrence or any-
cause death in the univariate analyses
Hazard Ratio (HR) *
(95% CI)
P value
Age (≥ 64 vs. < 64) 1.97 (0.87-4.44) 0.105
Sex (male vs. female) 1.13 (0.55-2.36) 0.738
Hypertension (yes vs. no) 1.22 (0.56-2.69) 0.619
Diabetes mellitus (yes vs. no) 2.16 (1.04-4.49) 0.039
Dyslipidemia (yes vs. no) 0.97 (0.46-4.05) 0.940
Smoking (yes vs. no) 0.74 (0.33-1.70) 0.465
Time from stroke onset to admission
(> 24 hours vs. ≤ 24 hours)
1.57 (0.73-3.39) 0.248
Qualifying event (Stroke vs. TIA) 1.22 (0.29-5.15) 0.783
NIHSS at admission (≥ 4 vs. < 4) 1.72 (0.75-3.91) 0.198
mRS at discharge (2-5 vs. 0-1) 2.06 (0.84-5.09) 0.117
IMCAD (occlusion vs. ≥ 50% stenosis) 1.09 (0.51-2.35) 0.819
* The hazard ratio and HR p-value of the each variable were determined with
the use of a Cox proportional-hazards regression model.
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ious times during the trial [34].
Current medical treatments for secondary prevention
of stroke mainly consist of risk factor control and
antithrombotic therapy. Whether anticoagulation is
superior to antiplatelet therapy for patients with symp-
tomatic intracranial artery stenosis remains controver-
sial. However, the Warfarin-Aspirin Symptomatic
Intracranial Disease (WASID) trial showed that warfarin
was not more effective than aspirin in the prevention of
recurrent stroke and carried a higher risk of serious
bleeding and death [28]. Recently, statins have been
shown to lead to regression of atherosclerosis, and one
trial showed a reduction in the risk of stroke [35,36].
Poor control of blood pressure and cholesterol appear
to be associated with a higher risk of a subsequent
stroke [37,38]. However, previous studies have shown
that only 35-47% of patients are treated to target after a
vascular event [38,39]. In our study, all patients continu-
ously used antithrombotics, more than half used antihy-
pertensive (ACEI or ARB), and more than one third
used statin. The finding that the long-term prognosis of
symptomatic MCAD in our study appeared to be more
favorable than a previously published study may be attri-
butable to a better compliance with antithrombotics and
pharmacological therapy of risk factors.
With regard to prediction factors, there is relatively lit-
tle information on the relationship between risk factors
and the recurrence of vascular events in patients with
intracranial artery disease. One study identified several
variables that were associated with an increased occur-
rence of ipsilateral stroke in the territory of symptomatic
intracranial stenosis in multivariate analyses [20]. In the
study, severe stenosis, stroke symptoms, and being a
woman were predictors of ischemic stroke. Another
study in a Chinese population identified DM as a risk fac-
tor for recurrent vascular events or death in a group of
patients with predominantly intracranial atherosclerosis
[40]. We also indentified the presence of diabetes melli-
tus as an independent potential predictor of long-term
outcome, stroke recurrence, or any-cause death. The pro-
gression of MCA stenosis detected by TCD was the only
factor independently associated with ipsilateral cerebral
ischemic events during follow-up [27,41].
Some limitations of our study should be noted. First,
because our study was hospital-based, it has the
Table 3 Multivariate analyses of the Cox proportional
hazard model of DM associated with stroke recurrence or
any-cause death, adjusted for age, sex, MCA stenosis vs.
occlusion, and the time from stroke onset to admission
Adjusted Hazard
Ratio
(95% CI)
P-value
Age (≥ 64 vs. < 64) 1.97 (0.87-4.50) 0.106
Sex (male vs. female) 0.98 (0.46-2.07) 0. 958
IMCAD (occlusion vs. ≥ 50% stenosis) 1.31 (0.60-2.87) 0.498
Time from stroke onset from
admission
(> 24 hours vs. ≤ 24 hours)
1.83 (0.84-4.02) 0.130
Diabetes Mellitus (yes vs. no) 2.26 (1.07-4.77) 0.032
IMCAD = Isolated Middle Cerebral Artery Disease; TIA = Transient Ischemic
Attack
Table 4 The comparisons of baseline characteristics and any-cause death during follow-up period between the
completed follow-up patients and lost to follow-up patients
IMCAD (N = 141) Completed follow-up (n = 113) Lost follow-up (n = 28) P
Age - mean (SD), years 64.4 (12.5) 64.7 (12.0) 63.1 (14.4) 0.558
Male sex (%) 74 (52.5) 61 (54.0) 13 (46.4) 0.474
Hypertension - no. (%) 87 (61.7) 73 (64.6) 14 (50.0) 0.155
Diabetes mellitus - no. (%) 40 (28.4) 29 (25.7) 11 (39.3) 0.152
Smoking (ever) - no. (%) 46 (32.6) 39 (34.5) 7 (25.0) 0.336
Dyslipidemia - no. (%) 53 (37.6) 41 (36.3) 12 (42.9) 0.520
Time from stroke onset to admission 0.527
≦24 hours -no. (%) 78 (55.3) 64 (56.6) 14 (50.0)
> 24 hours-no (%) 63 (44.7) 49 (43.4) 14 (50.0)
Qualifying event 0.457
Stroke - no. (%) 130 (92.2) 105 (92.9) 25 (89.3)
TIA - no. (%) 11 (7.8) 8 (7.1) 3 (10.7)
NIHSS on admission - mean (SD) 6.1 (6.0) 6.3(6.3) 5.3 (4.8) 0.420
mRS on discharge - mean (SD) 2.1 (1.5) 2.1 (1.6) 1.9 (1.4) 0.671
IMCAD 0.805
MCA stenosis ≥ 50% 98 (69.5) 78 (69.0) 20 (71.4)
MCA occlusion 43 (30.5) 35 (31.0) 8 (28.6)
Any-cause Death 20 (14.2) 16 (14.2) 4 (14.3) 1.00
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Page 6 of 8potential for a selection bias. Therefore, our results may
not be representative of the long-term prognosis of
MCAD in Korea. Second, we relied on MRA findings to
define MCAD rather than conventional angiography. In
addition, MRA could overestimate the degree of steno-
sis. Third, the rate of follow-up loss was 19%. However,
there were no significant differences in the baseline
characteristics and any-cause death between patients
lost to follow-up and those who completed the follow-
up (Table 4). The deaths of patients who were lost to
follow-up were verified by the information on death
source data from the Korean National Statistical Office
for the follow-up period. Therefore, the 19% lost to fol-
low-up rate may not have affected the overall clinical
outcomes. Finally, since some cases were investigated
through telephone interviews for stroke recurrence,
minor strokes might have been unnoticed.
Conclusions
We estimated the long-term prognosis of stroke patients
with isolated symptomatic MCAD under current medi-
cal management in Korea. Diabetes mellitus was found
to be a significant predictor for stroke recurrence or any
cause of death.
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